Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

S Shilpa Singh C Catherine E. Gleason M Min Fang Y Yasmin N. Laimon V Vishal Khivansara S Shanhai Xie Y Yavuz T. Durmaz A Aniruddha Sarkar K Kenneth Ngo V Varunika Savla Y Yixiang Li M Muhannad Abu-Remaileh X Xinyue Li M Marie-Anais Locquet B Bishma Tuladhar R Ranya Odeh F Frances Hamkins-Indik D Daphne He M Miles W. Membreno M Meisam Nosrati N Nathan N. Gushwa S Siegfried S. F. Leung B Breena Fraga-Walton L Luis Hernandez M Miguel P. Baldomero B Bryan M. Lent D David Spellmeyer J Joshua F. Luna D Dalena Hoang Y Yuliana Gritsenko M Manesh Chand M Megan K. DeMart S Sammy Metobo C Chinmay Bhatt J Justin A. Shapiro K Kai Yang N Nathan J. Dupper A Andrew T. Bockus J Jinshu Fang R Ramesh Bambal P Peadar Cremin J John G. Doench J James B. Aggen L Li-Fen Liu B Bernard Levin E Evelyn W. Wang I Iolanda Vendrell R Roman Fischer B Benedikt Kessler P Prafulla C. Gokhale S Sabina Signoretti A Alexander Spektor C Constantine Kreatsoulas M Marie Evangelista R Rajinder Singh D David J. Earp D Deepak Nijhawan P Pablo D. Garcia M Matthew G. Oser